217 related articles for article (PubMed ID: 32719151)
1. 'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'.
Goodman S M; George M D
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32719151
[TBL] [Abstract][Full Text] [Related]
2. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
Arthritis Rheumatol; 2017 Aug; 69(8):1538-1551. PubMed ID: 28620948
[TBL] [Abstract][Full Text] [Related]
3. Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying anti-rheumatic drugs after an average of 11.4-year follow-up.
Ren Y; Yang Q; Luo T; Lin J; Jin J; Qian W; Weng X; Feng B
J Orthop Surg Res; 2021 Jan; 16(1):84. PubMed ID: 33504345
[TBL] [Abstract][Full Text] [Related]
4. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
J Arthroplasty; 2017 Sep; 32(9):2628-2638. PubMed ID: 28629905
[TBL] [Abstract][Full Text] [Related]
5. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer BD; Chen AF; Davis M; Fernandez DR; Figgie M; Finlayson H; George MD; Giles JT; Gilliland J; Klatt B; MacKenzie R; Michaud K; Miller A; Russell L; Sah A; Abdel MP; Johnson B; Mandl LA; Sculco P; Turgunbaev M; Turner AS; Yates A; Singh JA
J Arthroplasty; 2022 Sep; 37(9):1676-1683. PubMed ID: 35732511
[TBL] [Abstract][Full Text] [Related]
6. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T
Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425
[TBL] [Abstract][Full Text] [Related]
7. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer BD; Chen AF; Davis M; Fernandez DR; Figgie M; Finlayson H; George MD; Giles JT; Gililland J; Klatt B; MacKenzie R; Michaud K; Miller A; Russell L; Sah A; Abdel MP; Johnson B; Mandl LA; Sculco P; Turgunbaev M; Turner AS; Yates A; Singh JA
Arthritis Rheumatol; 2022 Sep; 74(9):1464-1473. PubMed ID: 35722708
[TBL] [Abstract][Full Text] [Related]
8. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer BD; Chen AF; Davis M; Fernandez DR; Figgie M; Finlayson H; George MD; Giles JT; Gilliland J; Klatt B; MacKenzie R; Michaud K; Miller A; Russell L; Sah A; Abdel MP; Johnson B; Mandl LA; Sculco P; Turgunbaev M; Turner AS; Yates A; Singh JA
Arthritis Care Res (Hoboken); 2022 Sep; 74(9):1399-1408. PubMed ID: 35718887
[TBL] [Abstract][Full Text] [Related]
9. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
10. [Perioperative management of treatment of patients with inflammatory rheumatic diseases : Updated recommendations of the German Society of Rheumatology].
Albrecht K; Poddubnyy D; Leipe J; Sewerin P; Iking-Konert C; Scholz R; Krüger K
Z Rheumatol; 2022 Apr; 81(3):212-224. PubMed ID: 34928422
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
13. [Continue or interrupt? Antirheumatic treatment in elective surgery].
Albrecht K; Leipe J
Z Rheumatol; 2022 Aug; 81(6):492-500. PubMed ID: 35802185
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
15. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.
van Mulligen E; de Jong PHP; Kuijper TM; van der Ven M; Appels C; Bijkerk C; Harbers JB; de Man Y; Molenaar THE; Tchetverikov I; Goekoop-Ruiterman YPM; van Zeben J; Hazes JMW; Weel AEAM; Luime JJ
Ann Rheum Dis; 2019 Jun; 78(6):746-753. PubMed ID: 30954969
[TBL] [Abstract][Full Text] [Related]
16. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1111-1124. PubMed ID: 28620917
[TBL] [Abstract][Full Text] [Related]
17. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
19. Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
Rebić N; Sayre EC; Zusman EZ; Amiri N; Baldwin C; De Vera MA
Rheumatology (Oxford); 2020 Jul; 59(7):1514-1521. PubMed ID: 31628479
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological treatment of rheumatoid arthritis and its comorbidities].
Krüger K
Internist (Berl); 2018 Apr; 59(4):341-351. PubMed ID: 29508003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
